Press Releases

 

Enlyton, Ltd. Awarded National Cancer Institute SBIR Phase I Contract for Tumor Targeting Agent for SPECT Imaging of Cancer

September 2012 COLUMBUS, Ohio – Enlyton, Ltd., a technology leader in the development of cancer-specific tumor targeting agents for use in molecular imaging, has been awarded a   Phase I Small Business Innovation Research (SBIR) contract in the amount of $249,525 from the National Cancer Institute (NCI). The Phase I contract, which will cover approximately 10% of the total project cost, will be used to complete pre-clinical development of Enlyton’s antibody-based tumor targeting agent for SPECT imaging of adenocarcinomas (e.g., colorectal, esophageal, stomach, lung, ovarian, pancreatic).

Current cancer imaging and detection methods often fail to provide a clear picture of the extent of disease. SPECT (single photon emission computed tomography) is a sizeable market with a large base of installed scanners that has not been adequately supported for use in cancer imaging. Recent developments, e.g., SPECT/CT (computed tomography) fused imaging technology with attenuation correction, have improved SPECT performance and its clinical relevance for cancer imaging. The work of this contract will construct an antibody-based targeting agent that can rapidly accumulate in tumors while clearing from circulation quickly, and enable dosing and imaging within 24 hours using existing SPECT and SPECT/CT imaging platforms.

“Funding from this NCI SBIR contract will enable Enlyton, in collaboration with development partners Applied Biomolecular Technologies, Quanta BioDesign, and The Ohio State University, to complete this effort, and initiate the production of clinical grade antibody in the third quarter 2013”, added Enlyton CEO Jeff Bergen.

About Enlyton, Ltd.

Enlyton is integrating proprietary antibody technology into cancer-specific, antigen-directed targeting agents for use in cancer imaging, intraoperative cancer detection, and post-operative disease prognosis. Enlyton’s goal is to provide more accurate disease information, enabling oncologists to better determine the course of therapy, save lives, and reduce the overall cost of cancer treatment.

 

Fifteen Year Data Shows TAG-72 Antigen is a Major Factor in Patient Survival

July 2011 COLUMBUS, Ohio — Enlyton, Ltd., announced the publication of a 15-year follow-up analysis of long-term cancer survival comparing the presence or absence of tumor associated glycoprotein–72 (TAG-72) in patients after undergoing antigen-directed cancer surgery for colorectal cancer. TAG-72 is a shed tumor antigen that is produced by adenocarcinoma cells and accumulates in and around cancerous tissues.

The study concluded that the absence of detectable TAG-72 antigen within the surgical field at completion of antigen-directed cancer surgery for primary colorectal cancer is of significant prognostic value, conferring a long-term survival advantage to those in whom complete surgical removal of all tissues with detectable radiolabeled anti-TAG-72 uMAb was accomplished.

Dr. Edward W. Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) added, “We are excited with the conclusiveness of the data and the proof it demonstrates for continuing our development of TAG-72 based approaches for targeting cancer.”

The study, entitled, “Antigen-Directed Cancer Surgery for Primary Colorectal Cancer: 15-Year Survival Analysis” was published in the Annals of Surgical Oncology (DOI 10.1245/s10434-011-1880-3) by Povoski, Hatzaras, Mojzisik, Arnold, Hinkle, Hitchcock, Young, and Martin, authors from The Ohio State University and Enlyton, Ltd.

 

ViroMed and Enlyton Sign Licensing Agreement to Develop Humanized Antibody to TAG-72 for Cancer Detection

February 2011 SEOUL, KOREA  – ViroMed Co., Ltd. (KOSDAQ: 084990), a leading biotechnology company, announced that the company has entered into a licensing agreement with Enlyton, Ltd., an Ohio-based company developing improved methods of molecular imaging.

The agreement grants Enlyton exclusive worldwide rights to develop 3E8, a humanized monoclonal antibody (mAb) designed to target the tumor-associated glycoprotein 72 (TAG-72) antigen, for use in cancer detection and targeted drug delivery. Under the terms of the agreement Enlyton will pay ViroMed an upfront licensing fee with milestone payments totaling $4.7 million, and additional royalty payments based on revenues.

“We are pleased to have entered into an agreement with Enlyton, an up-and-coming company in the field of cancer detection,” said Paul Kim, Vice President of Business Development at ViroMed. “As the development time of antibodies for detection is comparatively faster than that of therapeutic antibodies, we expect to be able to enter this $8 billion dollar industry much sooner. This agreement is another important step in establishing ViroMed as a leading biotech company in Asia.” Enlyton CEO Jeff Bergen added, “This agreement provides Enlyton with access to an antibody that has been shown to offer great promise for use in cancer imaging and detection.”

About 3E8 3E8 is a humanized monoclonal antibody (mAb) designed to target the tumor associated glycoprotein 72 (TAG-72) antigen. TAG-72 is highly expressed (50-90%) in various epithelial derived cancers such as colonic adenocarcinomas, invasive ductal breast carcinomas, non-small cell lung carcinomas, epithelial ovarian carcinomas, and most pancreatic, gastric, and esophageal cancers. In preclinical testing, 3E8 showed a higher affinity to TAG-72 and had a lower immune response compared with previous TAG-72-specific mAb diagnostic imaging agents.

About ViroMed

ViroMed Co., Ltd. is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA/protein-based biopharmaceuticals and phytotherapeutics (botanical drugs/nutraceuticals). ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials ongoing in the US, Korea, and China. To learn more about the company and its products, visit www.viromed21.com.

 

New Data from Enlyton Supports Use of an Antigen-Directed, Cancer-Specific Targeting Agent for PET-Based Imaging
September 2010 COLUMBUS, Ohio  — Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton’s antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer. In the study, Enlyton’s targeting agent increasingly localized in tumor, while 18F-FDG did not. 18F-FDG also exhibited the tendency to localize in normal tissues. Dr. Edward Martin Jr. (Enlyton CSO and Professor of Surgery at The Ohio State University) said, “We are excited with the results of the study and the potential it offers for successful use of our cancer-specific targeting agent in clinical trials for preoperative, intraoperative, and postoperative PET-based imaging of colorectal cancer.”

The study, entitled, “124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results,” was published in the World Journal of Surgical Oncology (2010, 8:65) by Zou, Povoski, Hall, Carlton, Hinkle, Xu, Mojzisik, Johnson, Knopp, Martin, and Sun, authors from Enlyton, Ltd., The Ohio State University, and The University of Michigan. (View the whole article at http://wjso.com/content/8/1/65.)